Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.

Aim: To estimate the cost-effectiveness of cetuximab in combination with radiotherapy compared with radiotherapy alone, for the treatment of locally advanced head and neck cancer patients in Spain. Methods: A probabilistic Markov model (second-order Monte Carlo simulation) with a five-year time hori...

Descripción completa

Detalles Bibliográficos
Autores: Cabellos RÁ, Cacicedo J, Capafons SR, Los Santos Real H, Julián MB, Rubio-Rodríguez D, Rubio-Terrés C
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p5542
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/5542
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85217518357&doi=10.57264%2Fcer-2024-0116&partnerID=40&md5=64cc47a0da2374a7d9dbd5048e291a5b
Access Level:acceso abierto
Palabra clave:Spain, cetuximab, cost–effectiveness, locally advanced head and neck cancer, radiotherapy
id ES_5ca7cc00cbc3fcde882ed7c15da79e99
oai_identifier_str oai:i3pt.fundanetsuite.com:p5542
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.Cabellos RÁCacicedo JCapafons SRLos Santos Real HJulián MBRubio-Rodríguez DRubio-Terrés CSpain, cetuximab, cost–effectiveness, locally advanced head and neck cancer, radiotherapyAim: To estimate the cost-effectiveness of cetuximab in combination with radiotherapy compared with radiotherapy alone, for the treatment of locally advanced head and neck cancer patients in Spain. Methods: A probabilistic Markov model (second-order Monte Carlo simulation) with a five-year time horizon and quarterly Markov cycles was performed from the perspective of the Spanish National Health System (NHS). Results: The additional cost and quality-adjusted life-year (QALY) gain per patient receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was €4356 (95% CI: €4350-4362) and 0.2380 (95% CI: 0.2370-0.2391) QALY, respectively. The incremental cost per QALY gain was €18,303 (95% CI: €18,243-18,354) with a probability of cost-effectiveness of 65.4% for a willingness to pay of €30,000 per QALY gained. Conclusion: According to the results of this analysis, the addition of cetuximab to radiotherapy would be a cost-effective alternative to radiotherapy alone in the treatment of locally advanced head and neck cancer in Spain.Becaris Publishing2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/5542https://www.scopus.com/inward/record.uri?eid=2-s2.0-85217518357&doi=10.57264%2Fcer-2024-0116&partnerID=40&md5=64cc47a0da2374a7d9dbd5048e291a5bJournal of Comparative Effectiveness ResearchISSN: 20426305ISSNe: 20426313reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p55422026-06-21T15:30:37Z
dc.title.none.fl_str_mv Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.
title Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.
spellingShingle Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.
Cabellos RÁ
Spain, cetuximab, cost–effectiveness, locally advanced head and neck cancer, radiotherapy
title_short Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.
title_full Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.
title_fullStr Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.
title_full_unstemmed Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.
title_sort Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.
dc.creator.none.fl_str_mv Cabellos RÁ
Cacicedo J
Capafons SR
Los Santos Real H
Julián MB
Rubio-Rodríguez D
Rubio-Terrés C
author Cabellos RÁ
author_facet Cabellos RÁ
Cacicedo J
Capafons SR
Los Santos Real H
Julián MB
Rubio-Rodríguez D
Rubio-Terrés C
author_role author
author2 Cacicedo J
Capafons SR
Los Santos Real H
Julián MB
Rubio-Rodríguez D
Rubio-Terrés C
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Spain, cetuximab, cost–effectiveness, locally advanced head and neck cancer, radiotherapy
topic Spain, cetuximab, cost–effectiveness, locally advanced head and neck cancer, radiotherapy
description Aim: To estimate the cost-effectiveness of cetuximab in combination with radiotherapy compared with radiotherapy alone, for the treatment of locally advanced head and neck cancer patients in Spain. Methods: A probabilistic Markov model (second-order Monte Carlo simulation) with a five-year time horizon and quarterly Markov cycles was performed from the perspective of the Spanish National Health System (NHS). Results: The additional cost and quality-adjusted life-year (QALY) gain per patient receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was €4356 (95% CI: €4350-4362) and 0.2380 (95% CI: 0.2370-0.2391) QALY, respectively. The incremental cost per QALY gain was €18,303 (95% CI: €18,243-18,354) with a probability of cost-effectiveness of 65.4% for a willingness to pay of €30,000 per QALY gained. Conclusion: According to the results of this analysis, the addition of cetuximab to radiotherapy would be a cost-effective alternative to radiotherapy alone in the treatment of locally advanced head and neck cancer in Spain.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/5542
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85217518357&doi=10.57264%2Fcer-2024-0116&partnerID=40&md5=64cc47a0da2374a7d9dbd5048e291a5b
url https://i3pt.portalinvestigacion.com/publicaciones/5542
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85217518357&doi=10.57264%2Fcer-2024-0116&partnerID=40&md5=64cc47a0da2374a7d9dbd5048e291a5b
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Becaris Publishing
publisher.none.fl_str_mv Becaris Publishing
dc.source.none.fl_str_mv Journal of Comparative Effectiveness Research
ISSN: 20426305
ISSNe: 20426313
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408931470639104
score 15,81155

Similares en LA Referencia